Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has demonstrated significantly better results over conventional imaging for the direction of metastasis-directed therapy (MDT) for oligometastatic renal cell carcinoma (RCC). A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC. ...
Renal Cell Carcinoma Diagnostics
Advertisement
Dr. Dan Joyce discusses key SUO studies on RCC prognostics, personalized medicine, and advancements in treatment strategies.
Dr. Karam explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery.
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
The phase 3 ZIRCON trial demonstrated positive results with use of the agent for patients with ccRCC.
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Higher PSMA expression in non-metastatic ccRCC correlates with improved progression-free survival, study shows.
For the study, researchers identified potential protein biomarkers for diagnosing and prognosticating renal cell carcinoma.
Machine learning models can help with clinical decision making regarding renal function, according to new data.
[⁸⁹Zr]Zr-girentuximab PET-CT ccRCC prognostic imaging has a favorable safety profile and is highly accurate.
Advertisement
Video Insights
Conferene Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.